Hepatocellular carcinoma in children: Epidemiology and the impact of regional lymphadenectomy on surgical outcomes | Request PDF
Adoption of Hypofractionated Radiation Therapy for Breast Cancer After Publication of Randomized Trials | Request PDF
Vassiliki KARANTZA | Clinical Director | Merck & Co., Whitehouse Station | MSD | Department of Oncology
Oliver BOGLER | Professor (Full) | PhD | University of Texas MD Anderson Cancer Center, Texas | MD Anderson | Department of NeuroSurgery
Individual donors. Class notes - PDF Free Download
Breast Cancer in HIV-Positive Women: A Report of Four Cases and Review of the Literature | Request PDF
Vassiliki KARANTZA | Clinical Director | Merck & Co., Whitehouse Station | MSD | Department of Oncology
Vassiliki KARANTZA | Clinical Director | Merck & Co., Whitehouse Station | MSD | Department of Oncology
Oliver BOGLER | Professor (Full) | PhD | University of Texas MD Anderson Cancer Center, Texas | MD Anderson | Department of NeuroSurgery
Oliver BOGLER | Professor (Full) | PhD | University of Texas MD Anderson Cancer Center, Texas | MD Anderson | Department of NeuroSurgery
Primary spermatic cord tumors: Disease characteristics, prognostic factors, and treatment outcomes | Request PDF
Dr. Timothy M. Pawlik, MD | Columbus, OH | General Surgeon | US News Doctors
Fusion genes with ALK as recurrent partner in ependymoma-like gliomas: A new brain tumor entity? | Request PDF
Hepatocellular carcinoma in children: Epidemiology and the impact of regional lymphadenectomy on surgical outcomes | Request PDF
Vassiliki KARANTZA | Clinical Director | Merck & Co., Whitehouse Station | MSD | Department of Oncology
Oliver BOGLER | Professor (Full) | PhD | University of Texas MD Anderson Cancer Center, Texas | MD Anderson | Department of NeuroSurgery
Vassiliki KARANTZA | Clinical Director | Merck & Co., Whitehouse Station | MSD | Department of Oncology
Vassiliki KARANTZA | Clinical Director | Merck & Co., Whitehouse Station | MSD | Department of Oncology
Adoption of Hypofractionated Radiation Therapy for Breast Cancer After Publication of Randomized Trials | Request PDF
Vassiliki KARANTZA | Clinical Director | Merck & Co., Whitehouse Station | MSD | Department of Oncology
Vassiliki KARANTZA | Clinical Director | Merck & Co., Whitehouse Station | MSD | Department of Oncology
PDF) Malignant mesothelioma
Adoption of Hypofractionated Radiation Therapy for Breast Cancer After Publication of Randomized Trials | Request PDF
